CD44 and cancer: A novel form of metformin called Metformin-butyrate (MFB) has shown enhanced efficacy in specifically attacking the CD44+/high/CD24−/low cancer stem cell-like group in breast cancer and blocking the growth of mammospheres in contrast to regular metformin.